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Abstract
The treatment of choice for non-metastatic pheochromocytoma is surgical resection. Its goals are
to abolish catecholamine hypersecretion, normalize blood pressure, and prevent further tumor
growth or progression to metastatic disease. Data on long-term mortality and morbidity after
pheochromocytoma surgery are limited. We here report a retrospective study on the long-term
outcome after surgery for apparently benign pheochromocytoma at the Radboud University
Nijmegen Medical Centre. Data on clinical presentation, treatment, post-surgical blood pressure
and recurrence, metastasis and death were collected of 69 consecutive patients (January
1966–December 2000; follow-up: until death or January 2006). Survival was compared with
survival of a matched reference population. Two patients died of surgical complications. All ten
patients with metastatic disease (including three diagnosed at first surgery) died. At follow-up, 40
patients were alive and recurrence free and three patients were lost to follow up. Two patients
experienced a benign recurrence. MeanGS.D. follow-up was 10.2G7.5 (median 9, range 1–38)
years. Kaplan–Meier estimates for 5- and 10-year survival since surgery were 85.8% (95% CI:
77.2–94.4%) and 74.2% (95% CI: 62.0–86.4%) for patients versus 95.5 and 89.4% in the
reference population (P!0.05). Sixty-four percent of all patients with hypertension prior to surgery
showed a significant decrease in blood pressure, but remained hypertensive after surgery.
In conclusion, compared with the general population patients have a reduced life expectancy
following pheochromocytoma surgery, due to their risk of developing metastatic disease.
Only one-third becomes normotensive without antihypertensive medication. Therefore, lifelong
follow-up is warranted.
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Introduction
Pheochromocytoma (PHEO) is a rare catecholamine
producing tumor that derives fromchromaffin cells of the
adrenal medulla or extra-adrenal abdominal and thoracic
paraganglia (DeLellis et al. 2004, Lenders et al. 2005,
Pacak et al. 2005). Symptoms, signs and complications
of PHEO are mainly related to hypersecretion of
catecholamines. These include headache, palpitations,
diaphoresis, and hypertension. Once the biochemical
diagnosis of PHEO is established by plasma and/or urine
measurements of catecholamines and their metabolites
(Lenders et al. 2002), tumors are localized by anatomical
or functional imaging, such as 123I-MIBG scintigraphy
(Ilias et al. 2005).
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Treatment of non-metastatic PHEO consists of sur-
gical resection following preoperative pharmacolo-
gical sympathetic blockade (van der Horst-Schrivers
et al. 2006). The aims of surgery are abolishment of
catecholamine hypersecretion, normalization of blood
pressure, and prevention of further tumor growth and
progression to metastatic disease. The long-term
outcome of patients after PHEO surgery has been
addressed in a limited number of studies. Estimates of
benign and malignant recurrence rate after surgery
vary between 6 and 23% (Modlin et al. 1979, Scott &
Halter 1984, van Heerden et al. 1990, Pruszczyk et al.
1991, Plouin et al. 1997). Conflicting results of
previous cohort studies suggest that the life expectancy
after PHEO surgery is either normal (Stenstrom
et al. 1988) or decreased (Khorram-Manesh et al.
2005) when compared with the general population.
Furthermore, though PHEO is generally considered
to be a surgically curable cause of secondary
hypertension, blood pressure remains elevated after
surgery in a considerable number of patients
without recurrent disease (Plouin et al. 1997,
Khorram-Manesh et al. 2005).
The aim of this study was to investigate the long-
term follow-up of patients after surgery for apparently
benign PHEO. Survival was compared with results
obtained from a period-, age-, and gender-matched
Dutch reference population.
Methods
Patients
To evaluate long-term outcome, the study was
restricted to patients diagnosed with PHEO before
January 2001. From January 1966 until December
2000, 71 patients with a histologically confirmed
diagnosis of PHEO were evaluated at the departments
of General Internal Medicine and Endocrinology at the
Radboud University Nijmegen Medical Centre. In all
but four patients, initial PHEO surgery was performed
at our centre. Two patients were excluded from the
study: one patient was referred to our center because of
metastases and in a female patient who died during
Caesarian section the PHEO was found at autopsy.
This left 69 patients (44 females, 25 males) for
evaluation of follow-up after surgery for apparently
benign PHEO.
Initial work up, surgery, and follow-up
For the biochemical diagnosis of PHEO, plasma and
24-h urine were assayed by HPLC for concentrations
of catecholamines (plasma nZ59, urine nZ38) and
urine fractionated metanephrines (nZ12), according to
previously described procedures (Willemsen et al.
1995, 2003). CT (nZ57), MRI (nZ4), abdominal
ultrasound (nZ36) and 123I-MIBG scintigraphy
(nZ42) were employed to localize the tumor(s).
Except for three laparoscopic adrenalectomies, tumors
were resected by open procedures (including four
that initially started laparoscopically). Five patients
with bilateral tumors underwent staged open surgery.
Surgery was performed before 1990 in 43 per cent
(29 out of the 68) of patients. Plasma and urine
concentrations of catecholamines and metanephrines
were reassessed after a minimum of 1 month
post-surgery.
Data collection
Data on clinical presentation, biochemical, radio-
logical and histological diagnosis, and surgical and
pharmacological treatment were retrospectively col-
lected from the patients’ medical files in a standardized
fashion. Post-surgery follow-up data, including blood
pressure values, were collected until the end of
December 2005. In patients whose most recent visit
to our clinic took place before January 2005,
information on the current health status, blood
pressure, and antihypertensive treatment was updated
by telephone interviews of the patients and their
primary physicians.
Definitions
Hypersecretion of (nor)epinephrine was defined as
elevation of plasma and/or urine levels of (nor)-
epinephrine and/or its metabolite (nor)metanephrine
above the upper range of normal. Malignancy was
defined as histological evidence of tumor cells at sites
where chromaffin tissue is normally absent and/or by
evidence of distant metastases documented by imaging
studies (Linnoila et al. 1990). Recurrence was defined
as the reappearance of the disease as documented at
reintervention or by combined biochemical and
imaging tests, after complete eradication of the
tumor. Hypertension was defined as repeated office
readings of systolic and/or diastolic blood pressure
exceeding 140/90 mmHg and/or the use of antihyper-
tensive medication.
Data analysis and statistics
Survival of patientswho underwent successful resection
of apparently benign PHEO was estimated using the
Kaplan–Meier method and compared with the life
expectancy of a Dutch reference population that was
matched for age, sex, and period. Demographic data
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were obtained from Statistics Netherlands (Centraal
Bureau voor de Statistiek). The analysis was also
performed for a subgroup of patients with metastatic
PHEO. Pre- and post-surgery blood pressure values
were compared using paired sample t-test. Baseline
characteristics were compared between patients with
metastatic and non-metastatic PHEO, using unpaired
t-test, Wilcoxon rank sum test, and Fisher exact test,
when appropriate. Results are presented as meanGS.D.
unless mentioned otherwise. Statistical analysis was
performed using Statistical Package for the Social
Sciences (forWindows 12.0; SPSS, Chicago, IL, USA).
Results
Clinical presentation and diagnosis
Signs and symptoms at presentation are summarized in
Table 1. Symptoms occurred episodically in 82%
(55out of the 67) of patients, with a frequency of at
least daily in 42% (23 out of the 55). In two patients, an
adrenal tumor was found incidentally during work up
of colon carcinoma and chest pain respectively.
Seventy-seven percent (54 out of the 70) of patients
had hypertension. Apart from pre-surgical a- and
b-blockade, 64% (43 out of the 67) were on
antihypertensive drugs. Age at initial diagnosis of
PHEO was 46.1G15.6 (range 21–78) years. Hyperse-
cretion of norepinephrine only occurred in 35% (20 out
of the 57), epinephrine only in 7% (4 out of the 57), and
both epinephrine and norepinephrine in 58% (33 out of
the 57) of patients. PHEOs were located as follows: left
adrenal (nZ22), right adrenal (nZ33), bilateral
adrenal (nZ6), and extra-adrenal (nZ8: 5 retro-
peritoneal, three in the bladder). Ninety-three percent
(43 out of the 46) of tumors detected by anatomical
imaging (CT, MRI, and ultrasound) were positive on
123I-MIBG scintigraphy. Histological findings in all
tumors were consistent with PHEO. Fourteen patients
had an underlying familial tumor syndrome: five
neurofibromatosis, eight multiple endocrine neoplasia
(MEN) type 2A, and one MEN type 2B.
Follow-up
Of the 69 patients, two died within 4 weeks after surgery
(Table 2). In three patients, metastatic lesions were
detected intra-operatively. The remaining 64 patients
were included in the follow-up analysis. Follow-up of
these patients was 11.0G7.4 (median 9, range 1–38)
years. In 20 patients, the most recent clinical visit took
place more than one 1 year before the final analysis
(median 5, range 1–7 years). Three patients were lost to
follow-up at 2, 8, and 27 years after surgery.
Two patients experienced a benign recurrence (one
with MEN 2B). In one patient, initial surgery was
incomplete, and plasma catecholamines only
normalized after resection of the rest tumor.
Seven additional patients developed metastases,
within 1–14 years after the initial diagnosis (Table 3).
There were no significant differences between patients
withmetastatic and non-metastatic PHEOwith respect to
sex, age at diagnosis, pre-surgical plasma catecholamine
levels, and extra-adrenal tumor location (Table 4). All
patients with metastases died. Survival since the
diagnosis of metastases was 2.6G0.8 (range 0–6) years.
Twelve additional patients died during follow-up, all of
whomwere considered disease free although the cause of
death is unknown in 5 out of these 12 patients (Table 3).
Survival
For the 64 patients who underwent successful surgery for
non-metastatic PHEO, Kaplan–Meier estimates showed
5- and 10-year survival rates of 85.8% (95% CI:
Table 1 Symptoms and signs at initial presentation
Frequency (n)
Symptoms and signs Observed Reported a
Headache 77% (40/52) 60–90%
Palpitations 72% (39/54) 50–70%
Diaphoresis 87% (47/54) 55–75%
Pallor 57% (27/47) 40–45%
Nausea 70% (35/50) 20–40%
Flushing 33% (14/43) 10–20%
Tiredness 68% (39/57) 25–40%
Anxiety/panic attacks 65% (24/37) 20–40%
Weight loss 44% (27/61) 20–40%
Hypertension 77% (54/70) 50–60%
aLenders et al. 2005.
Table 2 Follow-up
Patients with PHEO, first evaluation between January
1966–December 2000 (nZ71)
Excluded:
Referred for metastatic PHEO, died (nZ1)
Heart failure during Caesarian section, post-mortem diagnosis
(nZ1)
Patients undergoing PHEO surgery (nZ69)
Intra- and post-operative findings:
Metastases apparent at surgery (nZ3)
Post-surgical mortality!4 weeks (nZ2, both non-metastatic)
Post-surgical follow-up of patients with apparently benign
PHEO (nZ64)
Lost to follow-up (nZ3)
Benign recurrence (nZ2)
Metastases, died (nZ7)
Died, recurrence and metastases free (nZ12)
Alive, recurrence and metastases free (nZ40)
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77.2–94.4%) and 74.2% (95% CI: 62.0–86.4%) versus
95.5 and 89.4% in the reference population respectively
(P!0.05, Fig. 1). The post-surgical survival of a
subgroup of patients who (eventually) developed
metastatic PHEO was well below that of a matched
reference population (Fig. 2). The survival of patients
with really benign PHEO (no metastases during follow-
up) was not significantly different from the reference
population (Fig. 3): 5- and 10-year survival rates 89.3%
(95%CI: 81.3–97.4%) and 84.1% (95%CI: 73.6–94.5%)
versus 96.2 and 90.9% in the reference population (ns).
Blood pressure and catecholamines
In patients with a post-surgical follow-up of at least 1
year, 67% (35 out of the 62) were hypertensive. Of 47
patients with hypertension prior to surgery, 17 (36%)
became and remained normotensive. Of the 30 recur-
rence-free patientswith hypertensionboth before surgery
and at most recent post-surgical follow-up, mean
blood pressure had decreased from 164G28/95G12 to
143G21/87G11 mmHg (P!0.001 for systolic and
diastolic blood pressure).
Plasma catecholamine levels normalized after
surgery, except in three patients with slightly elevated
levels, despite lack of recurrence on imaging studies.
Discussion
The main finding of our study is that patients undergoing
successful surgery for apparently benign PHEO have a
reduced life expectancy when compared with a sex, age,
and period-matched reference population. This can be
ascribed fully to the patients who developed metastatic
disease while survival was not reduced in the really
benign patients. We also show that only one-third of
recurrence-free patients become and remain normo-
tensive on the long-term following surgery.
Table 3 Mortality
Sex/age at
diagnosis
Year of
surgery Syndrome
Primary
tumor
location
Metastases-free
survival (y)
Post-surgery/
metastases
survival (y) Cause of death
Non-metastatic PHEO
F50 1984 – R adrenal – 0 Post-surgery sepsis
M47 1977 MEN2A L adrenal – 0 Post-surgery pulmonary
embolism
M54 1995 MEN2A LCR adrenal – 1 Car accident
F63 1998 – R adrenal – 2 Unknown
F30 1988 MEN2B LCR adrenal – 3 Unknown
F48 1966 – Extra-adrenal – 3 Sub-arachnoid hemorrhage
F52 1974 NF L adrenal – 4 Unknown
F62 1977 – R adrenal – 5 Metastatic colon carcinoma
F54 1990 NF R adrenal – 7 Mesenteric sarcoma
M73 1989 MEN2A LCR adrenal – 10 Gastric bleeding
F60 1993 – L adrenal – 11 Unknown
M67 1987 – R adrenal – 13 Cardiac
F64 1972 NF R adrenal – 14 Unknown
F51 1972 – L adrenal – 21 Myocardial infarction
Metastatic PHEO
F45 1989 – L adrenal 0 0/0 Multi organ failure post-
PHEO surgery
M46 1972 – L adrenal 0 0/0 Cachexia post-PHEO
surgery
M78 1998 – R adrenal 1 2/1 Suicide
M66 1974 – R adrenal 0 4/4 Complication of metastatic
PHEO
F32 1985 – L adrenal 3 5/2 Ruptured aortic aneurysm
F32 1988 – L adrenal 3 6/3 Unknown
M52 1974 – R adrenal 0 6/0 Unknown
M71 1992 – L adrenal 7 10/3 Pneumonia, metastatic
PHEO
F30 1984 – Extra-adrenal 5 10/5 Septic shock post-bowel
surgery
M75 1989 – L adrenal 14 16/2 Complication of abdominal
metastases
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Only a limited number of publications of the past 10
years provided long-term follow-up data on morbidity
and mortality after PHEO surgery (Plouin et al. 1997,
Goldstein et al. 1999, Amar et al. 2005, Khorram-
Manesh et al. 2005). Differences in study population,
length of follow-up, definitions of recurrent and
malignant disease, and analysis methods hamper
comparison of theses studies. The rates of benign
recurrence after successful surgery of non-metastatic
PHEO ranged from 3.3 to 6.1% (Plouin et al. 1997,
Amar et al. 2005, Khorram-Manesh et al. 2005), versus
3% in the present study. The prevalence of malignant
disease, ranged from 6.6 to 16% (Plouin et al. 1997,
Goldstein et al. 1999, Amar et al. 2005; Khorram-
Manesh et al. 2005), versus 14% in the present study.
Our observation of a 5-year metastases-free survival of
88% after successful surgery for really benign PHEO is
comparable with that of 92–94% found in these studies
(Plouin et al. 1997, Amar et al. 2005).
Since there are no established pathology criteria to
distinguish benign from malignant PHEO, clinical,
biochemical, and temporal characteristics have been
evaluated as surrogate predictors of malignant recur-
rence. Features that were implied to be associated with
shorter PHEO-free survival after surgery include extra-
adrenal tumor location, low epinephrine/epinephrineC
norepinephrine ratio (Plouin et al. 1997,Amar et al. 2005,
Table 4 Benign versus malignant PHEO
Benign PHEO
Malignant
PHEO
N 59 10
Sex (M/F) 19/40 6/4
Age at diagnosis (y) 45.2G15.3 51.1G16.3
Pre-surgery E/(ECNE) ratio 0.21G0.22
(nZ43)
0.14G0.24
(nZ10)
Extra-adrenal tumor 12% (7/59) 10% (1/10)
Benign: no metastatic lesions during follow-up. Malignant:
metastatic lesions during follow-up. M, male; F, female; E,
epinephrine; NE, norepinephrine.
Figure 1 Kaplan–Meier curve of survival after pheochromo-
cytoma surgery of 64 patients with apparently benign disease
compared with the Kaplan–Meier survival curve of a matched
reference population.
Figure 2 Kaplan–Meier curve of survival after pheochromo-
cytoma surgery of ten patients (eventually) diagnosed with
metastatic disease compared with the Kaplan–Meier survival
curve of a matched reference population.
Figure 3 Kaplan–Meier curve of survival after pheochromo-
cytoma surgery of 57 patients with benign disease compared
with the Kaplan–Meier survival curve of a matched reference
population.
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Khorram-Manesh et al. 2005, Plouin & Gimenez-Ro-
queplo 2006) and familial disease, especially SDHB-
relatedPHEO (Neumann et al. 2004,Benn et al. 2006). In
the present study, no predictors of malignant recurrence
were identified. However, the lack of significant
differences between patients with benign and malignant
PHEO may be related to a limited sample size.
Survival after uncomplicated PHEO surgery was
lower than in a Dutch reference population. In two
previous studies, the survival after PHEO surgery was
compared with the expected life expectancy of a
general reference population (Stenstrom et al. 1988,
Khorram-Manesh et al. 2005). In a Swedish cohort of
121 patients, 42 patients died during the observation
period versus 23.1 expected deaths in the control
population (P!0.001; Khorram-Manesh et al. 2005).
In a prior study performed at the same centre, however,
the observed and expected mortality were similar
(Stenstrom et al. 1988). Our study confirms that
patients with successfully resected PHEO still have a
reduced life expectancy. This excess mortality is
explained by the development of fatal metastatic
disease in 11% of patients. In patients with benign
PHEO, longstanding hypertension and catecholamine
excess prior to surgery can induce (partially) irre-
versible structural vascular changes (Plouin et al. 1997,
Khorram-Manesh et al. 2005), which might result in
increased cardiovascular mortality. The latter was not
confirmed by our study, although our study sample
does not allow for a comparison of cardiovascular
morbidity to that of the general population.
Our findings reinstate that despite radical surgery, a
substantial portion of recurrence-free patients remains
hypertensive. Although this refutes the original notion,
that PHEO is a surgically curable cause of hypertension,
blood pressure values of patients with persistent
hypertension were significantly lower post- than pre-
surgery. Two-thirds of patients with hypertension at
presentation were also hypertensive at most recent
follow. In previous studies, this frequency ranged from
38–71% (Pruszczyk et al. 1991, Plouin et al. 1997,
Khorram-Manesh et al. 2005). Age, familial hyper-
tension, and the presence of hypertension at 1 year after
surgery were identified as predictors of hypertension on
the long term (Plouin et al. 1997). This persistence of
hypertension is probably due to structural and
functional vascular abnormalities that may be induced
by the longstanding antecedent hypertension.
There are two issues that have to be kept inmindwhen
interpreting the Nijmegen cohort. The most important of
these is that outcome has been shown to be better in
PHEOpatients thatwere diagnosedmore recently than in
those diagnosed (many) years earlier. This is attributed to
the improvement of diagnostic, surgical (laparoscopic
surgery has replaced open resection), and anesthetic
techniques (Amar et al. 2005, Plouin & Gimenez-
Roqueplo 2006). All our patients were operated before
2001, mainly through open procedures. Secondly, the
prognosis of patientswithPHEOis largely determinedby
the underlying genotype. Genetic testing was not
systematically performed in all patients, partly due to
the fact that comprehensive genetic testing, including
SDHB mutations, became available after 2001. The
observed prevalence of disease-causing mutations of
20%might, in fact, be an underestimation, and the results
may theoretically be influenced by the portion of
unrevealed mutations.
In conclusion, patients who undergo successful
surgery for apparently benign PHEO have a reduced
life expectancy when compared with the general
population. The excess mortality is explained by the
development of metastatic disease during post-surgical
follow-up in some of the patients. By contrast, the
survival of patients who do not develop metastatic
disease is not different from that of the general
population. Hypertension persists in two-thirds of
recurrence-free patients. Lifelong follow-up of patients
who had surgery for PHEO is warranted.
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